{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-039478","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2025-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.090399+00:00","generated_at":"2026-05-23T05:45:33.083150+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Ocugen board to replace Drs. Fernandes and Whittington at 2025 annual meeting","bullets":["Prabha Fernandes, Ph.D., resigns; Marna C. Whittington, Ph.D., will not stand for re-election.","Both departures effective at Ocugen's 2025 Annual Meeting of Stockholders.","Board nominates Satish Chandran, Ph.D. (CEO, Prodigy Biotech) and Blaise Coleman (former CEO, Endo) to fill the vacancies.","Dr. Chandran has prior roles as CEO at Somahlution, CTO at Pfizer Biotherapeutics; Mr. Coleman brings 20+ years pharma finance/ops experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-039478","json":"https://secwatch.observer/filing/0001104659-25-039478.json","markdown":"https://secwatch.observer/filing/0001104659-25-039478.md","text":"https://secwatch.observer/filing/0001104659-25-039478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925039478/0001104659-25-039478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925039478/tm2513081d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:45:33.083150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"452b2244e9","claim":"Blaise Coleman was appointed as Director at Ocugen, Inc..","evidence_excerpt":"The Board plans to nominate Satish Chandran, Ph.D. and Blaise Coleman for election to the Board at the 2025 Annual Meeting to replace Dr. Fernandes and Dr. Whittington.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925039478/0001104659-25-039478-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Action","value":"nominated"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7ff984e033","claim":"Marna C. Whittington departed as Director at Ocugen, Inc..","evidence_excerpt":"Separately, on April 21, 2025, Marna C. Whittington, Ph.D., a member of the Board, the Compensation Committee of the Board, and a member and chair of the Audit Committee of the Board, informed the Company of her decision to not stand for re-election to the Board at the Company’s 2025 Annual Meeting.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925039478/0001104659-25-039478-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"not stand for re-election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d8fab15b7c","claim":"Prabha Fernandes resigned as Director at Ocugen, Inc..","evidence_excerpt":"Prabha Fernandes, Ph.D., FIDSA, a member of the Board of Directors (the “Board”) of Ocugen, Inc. (the “Company”), a member and chair of the Compensation Committee of the Board, a member of the Audit Committee of the Board and the Science and Technology Committee of the Board, informed the Company that she is resigning from the Board effective at the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925039478/0001104659-25-039478-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"df1afd8b36","claim":"Satish Chandran was appointed as Director at Ocugen, Inc..","evidence_excerpt":"The Board plans to nominate Satish Chandran, Ph.D. and Blaise Coleman for election to the Board at the 2025 Annual Meeting to replace Dr. Fernandes and Dr. Whittington.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925039478/0001104659-25-039478-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Action","value":"nominated"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}